HYDERABAD, India, Sept. 7, 2026 /PRNewswire/ -- According to Mordor Intelligence, the global snack bars market size is projected to grow from $21.94 billion in 2026 to $32.66 billion by 2031, registering a CAGR of 8.28% during the forecast period (2026-2031). Growth is being supported by rising demand for convenient, portable nutrition products that fit into commuting, school, and fitness routines. At the same time, tightening standards around health claims and changing consumer expectations are pushing manufacturers toward lower-sugar and higher-protein formulations. Strategic consolidation is also reshaping the category, while supply pressures affecting pea, whey, and rice protein isolates are increasing the importance of sourcing strategies and formulation flexibility.

Snack Bars Market Key Growth Factors

Convenience and Portable Nutrition Expand Consumption Occasions

Snack bars are increasingly positioned as practical nutrition formats for consumers managing busy lifestyles. Their portability allows brands to address multiple consumption occasions, including commuting, school routines, between-meal snacking, and pre- or post-workout use. This flexibility is helping snack bars compete with traditional packaged snacks while broadening their relevance across demographic groups.

The shift toward portable formats is also encouraging manufacturers to diversify product portfolios across cereal and granola bars, protein and energy bars, and fruit and nut or seed bars. As consumers increasingly combine convenience with nutritional expectations, brands are using format and formulation innovation to capture more frequent consumption.

Health-Claim Standards Drive Reformulation Toward Higher-Value Products

Regulatory changes are accelerating reformulation across the snack bars industry. Tighter standards surrounding the use of health claims, alongside growing consumer scrutiny of sugar content and nutritional composition, are encouraging manufacturers to reduce sugar and increase protein content.

This shift is creating opportunities for premium formulations designed to combine convenience with specific nutritional benefits. Higher-protein products are particularly relevant as consumers increasingly seek snacks that align with fitness and wellness routines. However, rising costs and supply pressures for key protein isolates are forcing manufacturers to balance nutritional ambitions with margin management.

Protein Supply Pressures Reshape Procurement Strategies

The growing use of pea, whey, and rice protein isolates is creating a supply-side challenge for snack bar manufacturers. Higher demand for protein-rich formulations is increasing exposure to raw material availability and input-cost fluctuations, placing pressure on gross margins.

Manufacturers are responding by negotiating longer-term supply agreements and diversifying protein sources to reduce dependence on individual inputs. This procurement shift is becoming an increasingly important competitive factor as companies seek to maintain consistent product quality and protect margins while expanding protein-focused portfolios.

"As global food safety mandates and functional beverage demand reshape pH control requirements, our structural analysis maps shifting demand across synthetic and bio-based sourcing. Built on direct supply-chain auditing and objective volume tracking, this report equips commercial leaders with a verified, defensible foundation for strategic procurement and investment," says Bhavesh-Narasinha Varute, Senior Research Manager.

Snack Bars Market Recent Industry Developments

April 2026 – ITC Limited finalized its acquisition of control over SproutLife Foods (YogaBar), strengthening its position in energy and protein bars and adding scale behind a digital-first brand.

March 2026 – Ferrero agreed to acquire Brazil-based Bold Snacks, a premium protein snack company with a growing portfolio of protein bars, marking Ferrero's entry into the better-for-you segment in South America.

Snack Bars Market Segment Insights

By Product Type

- Cereal and Granola Bars

- Protein/Energy Bar

- Fruit and Nut/Seed Bar

By Nature

- Conventional

- Organic

By Packaging Format

- Single-Serve

- Multipack

By Distribution Channel

- Supermarkets and Hypermarkets

- Convenience Stores

- Online Retail

- Specialty Stores

- Other Distribution Channels

Snack Bars Market Regional Insights

North America remains a significant market for snack bars, supported by established snacking habits, strong demand for portable nutrition, and continued innovation in protein and wellness-oriented products. Regulatory developments are also influencing product formulation as manufacturers reassess nutritional profiles and health claims.

Europe remains an important market for premium and health-focused snack bars, with manufacturers responding to consumer demand for lower-sugar and nutritionally differentiated products. Regulatory and labeling requirements continue to influence how brands position products and develop new formulations.

Asia-Pacific represents a strong long-term growth opportunity as urbanization, rising disposable incomes, and changing lifestyles increase demand for convenient packaged nutrition. Expanding modern retail and e-commerce channels are improving access to snack bar products across emerging consumer markets.

Discover the latest trends, growth opportunities, and competitive developments in the Snack Bars Market: https://www.mordorintelligence.com/industry-reports/global-snack-bars-market?utm_source=prnewswire

Competitive Landscape

The snack bars market is increasingly competitive as established food companies expand their portfolios into higher-growth snack and nutrition categories. Competitive strategies are centered on product innovation, protein positioning, healthier formulations, brand development, and broader distribution.

Industry consolidation is also becoming more significant as major food manufacturers use acquisitions to strengthen their exposure to faster-growing snacking categories. At the same time, supply chain management is becoming a key differentiator as manufacturers navigate protein ingredient costs and availability. Companies capable of securing reliable inputs while maintaining attractive nutritional and sensory characteristics are positioned to strengthen their market presence.

Key Companies in the Snack Bars Market

- General Mills Inc.

- Kellogg Company

- Mars Incorporated

- Mondelēz International Inc.

- Nestlé SA

Explore More Industry Research by Mordor Intelligence

Snack Foods Market: The global snack foods market size is estimated at USD 292.01 billion in 2026 and is projected to reach USD 358.58 billion by 2031, growing at a 4.2% CAGR from its 2025 valuation of USD 280.24 billion. Category demand is driven by shifting eating patterns, where round-the-clock snacking occasions increasingly substitute for structured meals, supported by rapid quick-commerce fulfillment infrastructure. To comply with tightening HFSS marketing restrictions and extended producer responsibility (EPR) mandates, CPG manufacturers are directing capital into clean-label reformulations and recyclable barrier packaging.

Dairy Snack Market Size: The global dairy snack market is estimated to expand from USD 266.70 billion in 2026 to USD 346.24 billion by 2031, registering a 5.37% CAGR from its 2025 base of USD 253.11 billion. Market expansion reflects a bifurcation between volume-dominant cheese snacks and high-growth yogurt formats, propelled by protein-conscious consumers and demand for probiotic fortification. While cartons and tetra-packs command core throughput, dairy processors are scaling flexible resealable pouches and direct-to-consumer delivery models to capture affluent urban shoppers trading up to organic and artisanal SKUs.

Fruit Snacks Market Share: The global fruit snack market is estimated at USD 22.02 billion in 2025 and is projected to reach USD 32.50 billion by 2030, advancing at an 8.10% CAGR. Robust growth is propelled by consumer migration toward whole-food, functional nutrition and certified organic label claims that offer cleaner alternatives to conventional confectionery. While North America represents the largest regional market, Asia-Pacific is accelerating rapidly due to urbanization and food labeling reforms, encouraging manufacturers to introduce innovative fruit chips, bars, and pouch formats.

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For media inquiries or further information, please contact: 

[email protected] 

Mordor Intelligence Private Limited

https://www.mordorintelligence.com/

SOURCE Mordor Intelligence Private Limited

Share this article

SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.

The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026.

National shareholder rights firm Hagens Berman is investigating the legal claims and urges Regeneron investors with substantial losses to submit your losses now. The firm also invites persons who may be able to assist in the investigation to contact its attorneys.

View our latest video summary of the allegations: youtu.be/rsW1-f8ARRs

Class Period: Aug. 1, 2025 – May 15, 2026

Lead Plaintiff Deadline: Sept. 14, 2026

Visit: www.hbsslaw.com/regn

Contact the Firm Now: [email protected]

                                       844-916-0895

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action:

The litigation is focused on the propriety of Regeneron's repeated optimism about the state of- (and changes to-) its Phase 3 trial of Fianlimab in combination with Libtayo as a first-line treatment for metastatic or locally advanced melanoma (the "Study").

The Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" – disease progression or death – determined the timing and statistical power of the primary PFS analysis.

The complaint alleges that Regeneron made false and misleading statements while failing to disclose critical information to investors. In particular, the lawsuit accuses the company and its management of not informing investors that the Study's preliminary statistical assumptions were flawed, the active treatment arm was not achieving meaningful differentiation over standard therapies, and achievement of its primary endpoint was unlikely.

Throughout the Class Period, Regeneron and the other defendants assured investors of their confidence in the Trial's achieving its primary endpoint even when events were slowing down. At one point, management said the slowing event rates are "because the test arms are performing well."

The truth began to emerge on April 29, 2026, when Regeneron first revealed that it decided to alter the Trial protocol such that "t]he primary analysis of progression-free survival will now consider all patients enrolled in the study with a minimum follow-up of 6 months."

One prominent analyst reportedly questioned whether the decision was made because, in contrast to management's expressed confidence, the "underlying PFS benefit may be insufficient to show statistical significance."

Then, on May 12, 2026, Regeneron admitted that the decision to alter the Trial protocol was made in response to "slow event rates," occurred nearly six months ago, and was "submitted it to all the global regulatory authorities in November, December timeframe."

Three days later, the final blow came. On May 15, 2026, Regeneron abruptly reported the "trial did not reach statistical significance of the primary endpoint of improvement in progression-free survival (PFS)."

"We're focused on whether Regeneron altered the Trial protocol without timely telling investors to intentionally mislead them because the defendants knew so-called blockbuster potential for the combination wasn't really there," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the pending claims in the suit.

If you invested in Regeneron and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

If you'd like more information and answers to other frequently asked questions about the Regeneron case and the firm's investigation, read more »

Whistleblowers: Persons with non-public information regarding Regeneron should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a securities class action has been filed after repeated surprise unit handpiece sales underperformance and gradual revelations of excess customer inventory levels driven by repeated, late-quarter, bulk discounts. The lawsuit seeks to represent investors who purchased or otherwise acquired PROCEPT common stock between February 28, 2024 and February 25, 2026.

National shareholders rights firm Hagens Berman is investigating legal claims that PROCEPT and the other Defendants violated the federal securities laws in their communications about sales of the company's single-use handpiece, a component of its proprietary Aquablation therapy used to treat patients with an enlarged prostate.

The firm encourages investors who suffered substantial losses to submit your losses now. Persons with knowledge who may be able to assist the investigation are invited to contact the firm's attorneys.

View our latest video summary of the allegations: youtu.be/N5u0rLr0QmA

Class Period: Feb. 28, 2024 – Feb. 25, 2026

Lead Plaintiff Deadline: Sept. 22, 2026

Visit: www.hbsslaw.com/prct

Contact the Firm Now: [email protected]

                                        844-916-0895

PROCEPT BioRobotics (PRCT) Securities Class Action:

The lawsuit alleges that during the Class Period, the defendants withheld crucial information from investors about PROCEPT's business, operations, and financial condition. Its focus is on the propriety of the company's statements and omissions related to handpiece sales practices in the U.S., including repeated touting of growth in those sales.

More specifically, the complaint alleges that (unknown to investors) the wrongdoing consisted of company's utilization of an extensive discount program to incentivize its customers to place bulk orders exceeding customers' procedures demands, pulling forward sales at the expense of future periods and, thereby, artificially inflating reported unit sales and revenues.

Investors began to learn the truth through a series of partial disclosures, each of which drove the price of PROCEPT shares sharply lower.

On August 6, 2025, PROCEPT announced its Q2 2025 financial results, revealing that the company's handpiece sales unexpectedly deteriorated, missing consensus estimates by a wide margin.

Then, on November 4, 2025 PROCEPT reported its Q3 2025 results, again missing expected handpiece unit sales. During the corresponding earnings call, management slashed annual handpiece unit sales guidance to allow for the "optimization of field inventory[,]" and said PROCEPT had not "been managing customer inventory[,]" adding that some customers were "probably carrying too much."

Finally, on February 25, 2026 PROCEPT announced Q4 2025 results. For the first time, the company disclosed the actual number of procedures in the field and revealed that U.S. handpiece sales materially exceeded procedures in each quarter since Q1 2023.

Of concern was that cumulative excess customer inventory of handpieces were over 10,000 units and U.S. handpiece sales sequentially cratered by 30%. Management then said that the company was eliminating its (previously undisclosed) bulk order discount program which was designed to incentivize customers to make large purchases during "the final weeks" of every quarter. The problem was the bulk order discount program essentially ate into future sales as customers already had excess inventories.

As a result of these events, by February 25, the price of PROCEPT shares had steadily declined by $22.06, or over 48% from the close on August 6, 2025.

"We're focused on whether PROCEPT may have intentionally pulled-in sales from future quarters to make it seem like the company was meeting expectations and, if so, whether the company had been sufficiently transparent in its investor communications," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in PROCEPT and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

If you'd like more information and answers to other frequently asked questions about the PROCEPT case and the firm's investigation, read more »

Whistleblowers: Persons with non-public information regarding PROCEPT should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Cogent Communications Holdings (NASDAQ: CCOI) that a securities class action has been filed after questions arose about a key metric's indication about actual growth prospects. The lawsuit seeks to represent investors who purchased or otherwise acquired Cogent common stock between February 29, 2024 and May 1, 2026.

National shareholders rights firm Hagens Berman is investigating legal claims that Cogent and the other defendants violated the federal securities laws in connection with its disclosures about the importance of wavelength backlog convertible to recognizable revenues.

The firm encourages investors who suffered substantial losses to submit your losses now. Persons with knowledge who may be able to assist the investigation are invited to contact the firm's attorneys.

Class Period: Feb. 29, 2024 – May 1, 2026

Lead Plaintiff Deadline: Sept. 21, 2026

Visit: www.hbsslaw.com/ccoi

Contact the Firm Now: [email protected]

                                        844-916-0895

Cogent Communications Holdings (CCOI) Securities Class Action:

The lawsuit challenges the propriety of Cogent's disclosures about its optical wavelength "backlog," assurances that this metric was somehow an indicator of its expected growth and, by extension, its reasonably expected revenue growth and stock's value.

The complaint alleges that Cogent's wavelength backlog was an illusory touted measure and unlikely to ever convert to revenue, that large quantities of customers in the backlog were unable or unwilling to accept delivery even if Cogent was in a position to provision the wavelength in a timely manner and that, as a result, the company materially misrepresented customer demand for its optical wavelength services and the nature of its backlog.

Cracks in Cogent's early Class Period narrative began to emerge on February 27, 2025. That day, Cogent reported disappointing Q4 and FY 2024 financial results and revealed a 20% sequential decline in its backlog and that it removed 1500 orders because many were over one year old. Surprised, the market sent the price of the stock steeply lower.

Then, on May 8, 2025, the company reported disappointing Q1 2025 results and said it had more installation capacity than orders ready to be installed. Management said, "we built a funnel of wavelength opportunities with no defined installation window […] [a]nd as expected, the majority of that funnel fell out." The market's reaction was similar to February.

In apparent recognition that investors lost faith in the wavelength backlog story, the company abruptly ceased providing backlog data on February 20, 2026, when it reported Q4 and FY 2025 results. Again, the market sent the price of Cogent shares steeply lower.

Finally, on May 4, 2026, Cogent reported its Q1 2026 results that again disappointed on wavelength revenue and customer connections. Management conceded "[o]n wavelength installs, we have seen a variety of customers pushing out their acceptance[]" and "[w]e actually provisioned more wavelengths in the quarter than we did in the previous quarter, but the customers did not accept them."

"We're focused on whether Cogent and its management intentionally promoted wavelength backlog and funnel as a way to misrepresent both the company's actual ability to convert them to earned revenues and the real company-centric wavelength demand," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in Cogent and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now »

If you'd like more information and answers to other frequently asked questions about the Cogent case and the firm's investigation, read more »

Whistleblowers: Persons with non-public information regarding Cogent should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Wix.com Ltd. (NASDAQ: WIX) faces a securities class action in the wake of mid-May's massive 27% drop in the price of the company's shares after Wix announced its Q1 2026 financial results. Among the disappointments, operating expenses unexpectedly spiked 46% year-over-year leading to questions about the company's ability to defend its core business.

The case is Yappi v. Wix.com Ltd., et al., No. 26-cv-08852 (N.D. Ill.).

The lawsuit seeks to represent investors who purchased or otherwise acquired Wix securities between February 19, 2025 and May 12, 2026.

National shareholders rights firm Hagens Berman continues its investigation into claims that Wix violated the federal securities laws and urges Wix investors who suffered significant losses to contact the firm now to discuss their rights.

Class Period: Feb. 19, 2025 – May 12, 2026

Lead Plaintiff Deadline: Sept. 22, 2026

Visit: www.hbsslaw.com/wix

Contact the Firm Now: [email protected]

                                        844-916-0895

Wix.com Ltd. (WIX) Securities Class Action:

Global web development platform company Wix faces increasing competitive challenges posed by vibe coding, a software development trend where a person builds apps or websites by giving plain-language instructions to an AI rather than writing code line-by-line.

To confront this challenge, Wix positioned AI initiatives, Base44 and Harmony, as its two-pillar response to the vibe coding trend threatening the company's core business.

The company has provided numerous assurances to investors, including that "[w]e expect innovation-driven growth to be accompanied by high impact but disciplined investments to fully unlock the market opportunity ahead for both Wix and Base44." In addition, Wix has emphasized "[e]arly Wix Harmony performance is better than expected, with improved conversion and monetization[,]" and "[t]ogether, Wix Harmony and Base44 open up the world of what's possible on Wix[.]"

The complaint alleges that Wix made false and misleading statements while failing to disclose that, with respect to its AI product offerings, Wix overstated their competitiveness and performance, understated the costs associated with developing and promoting them and, accordingly, overstated their commercial and financial benefits.

Investors began to learn the truth on May 21, 2025, when Wix provided 2025 revenue guidance falling short of analyst expectation and fueling concerns about the company's competitiveness. Then, on November 19, 2025, Wix reported its Q3 2025 results indicating rising post-Base44-acquisition costs (AI compute and marketing) were having a material negative impact on its financial results. Each of these triggered sharp selloffs in the price of the stock and triggered analyst downgrades on concerns over core business growth deceleration, increasing costs, and competitive positioning.

Finally, on May 13, 2026, Wix revealed aggressive and front-loaded AI compute expenses for Harmony and Base44. More specifically, the rapid expansion of Base44 and Harmony rollout radically altered Wix's cost structure primarily through front-loading sales and marketing ("S&M") expenses. Collectively, the initiatives drove non-GAAP S&M expenses to $190.7 million, a year-over-year 88% increase that caused the company's non-GAAP operating margin to collapse from 21% during the prior year period to just 5% while sending its quarterly operating expenses up 46% from the prior year period.

During the earnings call that day, management acknowledged that professional development customers were using competing AI tools, the Harmony platform had "holes" and "missing capabilities," and there had been delays in delivering product updates and innovation to professional developer customers resulting in Wix falling behind their workflows and needs.

The market swiftly reacted that day, scalping over $1.1 billion from Wix's market capitalization and prompting analysts' surprise over the magnitude of the margin miss.

"We're investigating whether Wix may have intentionally understated the adverse effects of its AI initiatives on its operating results," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation.

If you invested in Wix and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »

If you'd like more information and answers to frequently asked questions about the Wix case and the firm's investigation, read more »

Whistleblowers: Persons with non-public information regarding Wix should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities practice group—notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration's (FDA) recent decision to extend the review period for Capricor's Biologics License Application (BLA), underscoring the ongoing regulatory and disclosure scrutiny surrounding the company.

Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now.

FDA Extends BLA Review Following Post-AdCom Submissions

On Aug. 24, Capricor announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) target action date for Capricor's lead investigational cell therapy, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD), moving the decision date from August 22, 2026, to November 22, 2026.

The agency classified Capricor's recent submission—which follows a turbulent July 2026 Advisory Committee meeting and includes 24-month open-label extension data from the Phase 3 HOPE-3 study alongside a request to pivot toward a refined indication focused solely on upper limb function—as a major amendment.

Securities Class Action Details & Overview

- Class Period: Dec. 17, 2025 – July 26, 2026

- Lead Plaintiff Deadline: Sept. 28, 2026

- Visit: www.hbsslaw.com/capr

- Contact the Firm Now: [email protected] / 844-916-0895

Core Allegations and Background

- Material Misleading Statements Regarding Clinical Trial Data and SAP Changes: The lawsuit alleges that Capricor and certain executives made materially false and misleading statements regarding the clinical trial data and regulatory pathway for its lead product candidate, Deramiocel, intended to treat Duchenne muscular dystrophy (DMD). Specifically, defendants allegedly failed to disclose that they adopted changes to the pre-specified statistical analysis plan (SAP) without agreement from the U.S. Food and Drug Administration (FDA) prior to resubmitting its Biologics License Application (BLA).

- The HOPE-3 Trial Breakthrough and Subsequent Capital Raise: On December 3, 2025 Capricor announced "Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy." The company's CEO said "HOPE-3 delivered strong and definitive evidence that Deramiocel can meaningfully improve the course of Duchenne muscular dystrophy, demonstrating statistically significant improvements in both skeletal and cardiac function." Driven by these claims, Capricor's share price surged 370% to close up $23.60 on December 3, 2025. The following day, the company launched a public stock offering of approximately 6 million shares priced at $25 per share.

- FDA Briefing Document Reveals SAP Changes and Triggers 64% Stock Collapse: Capricor's public assurances unraveled on July 27, 2026, when the FDA published briefing documents ahead of an Advisory Committee meeting. The documents revealed that Capricor made unagreed-upon post-hoc modifications to its pre-specified Statistical Analysis Plan (SAP). The FDA stated that the HOPE-3 study "did not meet its pre-specified primary and secondary efficacy endpoints showing no statistically significant difference between deramiocel and placebo at 12 months." Capricor shares crashed roughly 64% in a single day to close at $7.00. An Advisory Committee subsequently voted 9–3 against the efficacy of the drug, compounding investor losses.

Hagens Berman's Investigation

"We're focused on investors' losses and uncovering the full scope of how management characterized these trial endpoints and undisclosed modification," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation on the claims alleged in the pending suit.

What Affected CAPR Investors Should Do

If you purchased or acquired Capricor securities between December 17, 2025, and July 26, 2026, and suffered significant financial losses, you have until September 28, 2026, to ask the court to appoint you as lead plaintiff. You do not need to seek lead plaintiff status to share in any potential recovery.

To learn more about your legal options, submit your information to Hagens Berman, visit www.hbsslaw.com/capr, call Reed Kathrein at 844-916-0895, or email [email protected].

If you'd like more information and answers to frequently asked questions about the Capricor case and the firm's investigation, read more »

Whistleblowers: Persons with non-public information regarding Capricor should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Pentair plc (NYSE: PNR) that a securities fraud class action lawsuit filed against the company has been expanded to cover an earlier class period. Investors who suffered substantial losses are urged to submit their losses now.

CASE DETAILS

Expanded Class Period: March 11, 2025 – July 14, 2026 (Previously April 28, 2026 – July 14, 2026)

Lead Plaintiff Deadline: Oct. 2, 2026

Contact Hagens Berman: Visit www.hbsslaw.com/pnr, email [email protected], or call (844) 916-0895

ALLEGED MISCONDUCT & EXPANDED CLASS PERIOD

The new class action lawsuit alleges that beginning on March 11, 2025, Pentair plc and certain of its top executives made a series of materially false and misleading statements and omitted critical adverse operational information regarding Pentair's financial health, channel inventory, and internal controls.

Specifically, the lawsuit alleges Defendants failed to disclose that:

- Pentair was experiencing severe, undisclosed channel inventory destocking—particularly within its core Pool segment.

- The company engaged in unsustainable channel-loading and sales practices with distributors to artificially inflate short-term financial metrics.

- As a result, Pentair's positive statements regarding its business, full-year financial guidance, and operating income lacked a reasonable basis.

THE DISCLOSURE & MARKET REACTION

The complaint alleges that the artificial inflation in Pentair shares came to an abrupt end on July 14, 2026, after the market closed, when Pentair shocked investors by pre-announcing preliminary second-quarter 2026 financial results that fell substantially below consensus estimates.

The disclosures revealed severe operational headwinds:

- Massive Revenue Miss: Sales were expected to be approximately $930 million—a drastic miss against prior forecasts of $1.14 billion. The company disclosed that inventory destocking in the Pool channel negatively impacted Pool segment sales by approximately $170 million and income by approximately $105 million.

- Full-Year Guidance Slashed: Pentair dramatically cut its full-year 2026 outlook, reversing earlier projections. Full-year sales were projected to be down approximately 4% to 7%, compared to prior guidance of up 2% to 4% growth.

- Abrupt CFO Departure: Compounding the shock, Pentair announced the immediate departure of its Chief Financial Officer, Nicholas Brazis, after serving in the role for only four months, raising questions regarding internal controls and financial reporting.

Following these disclosures, Pentair's stock price plummeted 15% in a single session—losing $11.35 per share to close at $64.33 on unusually heavy trading volume on July 15, 2026.

"We are closely examining the timing of these disclosures, the sudden departure of the CFO after only four months, and the severe impact of channel destocking on Pentair's financial health," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the alleged claims.

What Affected PNR Investors Should Do

If you purchased or acquired Pentair common stock between March 11, 2025, and July 14, 2026, and suffered significant financial losses, you have until October 2, 2026, to ask the court to appoint you as lead plaintiff.

To learn more about your legal options, submit your information to Hagens Berman, visit www.hbsslaw.com/pnr, call Reed Kathrein at 844-916-0895, or email [email protected].

If you'd like more information and answers to other frequently asked questions about the Pentair case and the firm's investigation, read more »

Whistleblowers: Persons with non-public information regarding Pentair should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

SAN FRANCISCO, Sept. 7, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman encourages investors in DNOW Inc. (NYSE: DNOW) who suffered substantial losses submit your losses now. A securities class action lawsuit has been filed regarding potential violations of federal securities laws involving DNOW's acquisition of MRC Global Inc. and undisclosed enterprise software integration failures in the merger proxy materials.

- Lead Plaintiff Deadline: Oct. 2, 2026

- Defined Investor Class and Record Date: Shareholders who held DNOW common stock as of the August 5, 2025 record date and were thus entitled to vote at DNOW's September 9, 2025 special meeting on the merger of DNOW and MRC Global

Investors with significant losses are urged to contact the firm to review their options:

- Visit: www.hbsslaw.com/dnow

Allegedly Misleading Proxy Materials:

The suit alleges that the Proxy Materials misrepresented and omitted to disclose challenges posed with DNOW's merger with MRC Global Inc. as a result of material issues affecting MRC Global's new ERP system.

The Truth Allegedly Emerges

- November 5, 2025 — Reassurances Before Acquisition: The complaint alleges that on DNOW's Q3 2025 earnings call—the day before closing the merger—management assured investors that MRC Global had implemented a "state-of-the-art" Enterprise Resource Planning (ERP) system that promised "improved inventory management, order processing efficiency, and supply chain optimization." DNOW allegedly minimized integration risks, reassuring the market that MRC's past software glitches were merely an "isolated, one-time event."

- February 20, 2026 — The Disclosures: DNOW reported its Q4 and full-year 2025 financial results, revealing that MRC revenues had sharply declined due to "persistent ERP challenges" and acknowledging that MRC's software implementation was, in fact, an "obstacle."

- Operational Flaws & Guidance Delay: Management conceded that flawed software design architecture caused severe operational slowdowns, impeded customer service, and required substantial unexpected capital expenditure to remediate. Consequently, DNOW was forced to delay its sequential and full-year 2026 financial guidance.

- Market Impact: On this news, DNOW stock crashed 19% in a single trading session.

Statement from Hagens Berman Partner Reed Kathrein

"We are focused on whether the Proxy Materials downplayed ERP integration failures at MRC Global allowing management to push the deal through, as the complaint alleges," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the claims in the pending suit.

What DNOW Investors & Whistleblowers Can Do

- DNOW Investors: If you purchased DNOW common stock and sustained significant losses, you may be eligible to take an active role in the class action. The court-appointed lead plaintiff deadline is October 2, 2026. Submit your loss details here.

- Whistleblowers: Persons with non-public information regarding DNOW should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

SOURCE Hagens Berman Sobol Shapiro LLP

Share this article

Pentair plc (PNR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa., Sept. 7, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Pentair plc.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN PENTAIR PLC (PNR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE OCTOBER 2, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?

The complaint filed in this class action alleges that between March 11, 2026 and July 14, 2026, Defendants failed to disclose to investors: (1) that there was significant destocking of inventory in the Pool channel; (2) that, as a result, the Company's sales and operating income were adversely affected; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact Us To Participate or Learn More:

If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:

Howard G. Smith, Esq.,

Law Offices of Howard G. Smith,

3070 Bristol Pike, Suite 112,

Bensalem, Pennsylvania 19020,

Call us at: (215) 638-4847

Email us at: [email protected],

Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

[email protected]

www.howardsmithlaw.com

SOURCE Law Offices of Howard G. Smith

Share this article

Internationaler Programm-Partnertag von Bibel TV: Wie erreicht christlicher Content die Menschen von heute?

Medienmacher aus fünf Ländern diskutieren über KI, Authentizität und neue Formate

Hamburg (ots)

Wie können christliche Medien Menschen erreichen, die mit Kirche und Glauben bislang wenig Berührung haben? Und welche Rolle spielen dabei Künstliche Intelligenz, Social Media und neue Streamingformate? Diese Fragen standen im Mittelpunkt des Internationalen Programm-Partnertag von Bibel TV am 3. September in Hamburg. Neun Referenten aus den USA, Frankreich, Dänemark, Österreich und Deutschland diskutierten über die Zukunft christlicher Medien und die Frage, wie sich technologische Innovation und authentische Inhalte miteinander verbinden lassen.

Matthias Brender, Geschäftsführer von Bibel TV, erläuterte die Geschichte der Christianisierung mit der Erkenntnis, dass im Verlauf der Geschichte des Christentums inzwischen die Entwicklungskurve nach unten zeige und in den letzten Jahrzehnten ein massiver Verlust an Christen zu verzeichnen sei. Diesen Verlust will Bibel TV durch Missionsarbeit ausgleichen - wie durch das Projekt "Bibel TV Next Mission".

Auch die Mediennutzung ändere sich fundamental und dynamisch. Für Bibel TV als christliches Medienhaus stelle sich die Frage, wie es Menschen dort erreichen kann, wo sie heute Medien konsumieren - ohne dabei die Authentizität der christlichen Botschaft aufzugeben. Mit der Initiative "Bibel TV Next Mission" wolle man neue Wege gehen und aus den Erfahrungen vergangener Projekte lernen, so Brender.

Ein Schwerpunkt dabei ist auch Künstliche Intelligenz. Der französische Digitalpionier und Medienunternehmer Éric Célérier, Gründer von u.a. "Jesus.net" und "HelloBible", verglich die KI mit der Erfindung des Buchdrucks. Wie Martin Luther vor rund 500 Jahren eine (fast) neue Technologie genutzt habe, um seine Botschaft einem Massenpublikum zugänglich zu machen, stelle sich heute die Frage, wer die Möglichkeit der Künstlichen Intelligenz für christliche Inhalte nutzen werde. Entscheidend sei dabei nicht mehr, ob KI eine Chance oder Bedrohung darstelle, sondern wie sie eingesetzt werde.

Norbert Grill, CEO von Big Blue Marble, und Iva Hauk, Area Sales Manager DACH, stellten den offenen technischen Standard C2PA vor. Das Verfahren bekämpft Desinformationen, indem es offenlegt, dass die gestreamten Inhalte authentisch sind. Manipulationen an Inhalten werden automatisch sichtbar, Ursprung und Bearbeitungen können einfach nachvollzogen werden. Dieser Authentizitätsnachweis soll in erster Linie das Vertrauen der Nutzer in digitale Medien stärken und Contentanbieter vor Vorwürfen der Manipulation schützen. Big Blue Marble ist ein international tätiger Medientechnologie-Experte für Broadcasting und Streaming, der aus dem Zusammenschluss der österreichischen ORF-Tochter ORS Group und dem Streaming-Spezialisten Insys Video Technologies hervorgegangen ist.

Dass KI nicht nur technische Prozesse verändert, sondern auch die Produktion und Adaption von Inhalten, zeigte Thorsten Lork, Storyteller und Creative Expert. Am Beispiel des US-amerikanischen Pastors und TV-Predigers Rick Warren erläuterte er, wie erfolgreiche Inhalte für andere Länder und Kulturräume adaptiert werden können. KI kann dabei Übersetzungen unterstützen und optimieren - die kulturelle und emotionale Einordnung bleibt jedoch entscheidend für die Authentizität.

Dass neue digitale Formate auch wirtschaftlich tragfähig sein können, zeigte Jan Bertil Dahms, Senior Vice President des Streaming-Technologieunternehmens Leyra. Insbesondere kurze, vertikal produzierte Formate für die Nutzung auf Smartphones eröffneten neue Möglichkeiten, spezifische Zielgruppen anzusprechen. Entscheidend sei, Inhalte konsequent an den Bedürfnissen und Sehgewohnheiten der jeweiligen Zielgruppe auszurichten.

Jared Geesey von Angel Studios zeigt anhand der weltweiten Erfolgsgeschichte von "The Chosen", wie christliche Themen ein Publikum erreichen können, das bislang keinen direkten Bezug zum christlichen Glauben hat. Entscheidend sei, Geschichten so zu erzählen, dass sie emotional und kulturell anschlussfähig seien. Angel Studios zählt zu den wichtigsten internationalen Programmpartnern von Bibel TV.

Um Authentizität und die unmittelbare Begegnung mit Menschen ging es auch bei Georg Schuster, CEO der österreichischen Uplink Medien GmbH. Unter dem Titel "Echt seinc- in welcher Haltung möchten wir den Menschen begegnen?" stellte er neue missionarische Kampagnen aus Österreich vor. Kurt Johansen, Executive Director des internationalen christlichen Mediennetzwerks SAT-7, berichtete über die Arbeit des Senders im Nahen Osten und in Nordafrika. SAT-7 produziert u.a. Programme in Arabisch, Farsi und Türkisch und setzt dabei auf Inhalte, die Menschen in ihrer jeweiligen Landessprache und Lebenswelt erreichen.

Zum Abschluss des Partnertages stellte Norman Rentrop, Verleger sowie Gründungsmitglied und Gesellschafter von Bibel TV, die nächste Initiative von "Bibel TV Next Mission" vor: Bibel TV will in Deutschland in 42 Millionen Haushalten das Lukas-Evangelium zugänglich machen. Unter dem Motto "Schau in die Bibel - gut für die Seele" soll die Bibel dabei bewusst auch Menschen erreichen, die bislang keinen Zugang zu christlichen Medien oder kirchlichen Angeboten haben.

"Der Programm-Partnertag hat gezeigt, dass christliche Medien vor spannenden und herausfordernden Aufgaben stehen: Wir müssen technologisch offen und experimentierfreudig sein und dabei bei unserer Aufgabe bleiben, die uns ausmacht: Die christliche Botschaft zu verbreiten und glaubwürdige Geschichten zu erzählen, die Menschen Mut und Hoffnung geben", sagt Beate Busch, Executive Vice President und Prokuristin Bibel TV. "Der Austausch mit unseren internationalen Medienpartnern ist dabei ein wichtiger Impuls für die weitere Entwicklung von Bibel TV."

Über Bibel TV: Bibel TV ist ein christlich-ökumenisches Medienhaus mit Sitz in Hamburg und größtenteils durch Spenden finanziert. Neben dem 24-stündigen Fernsehprogramm und einem Programmheft gehören zu dem Angebot von Bibel TV eine Mediathek, verschiedene Apps und Social Media-Kanäle. Auf seiner Streaming-Plattform verbreitet Bibel TV auch christlichen Content anderer Anbieter (EWTN, Hope TV, K-TV). Über www.meingottesdienst.com/ überträgt Bibel TV Live-Gottesdienste aller christlichen Konfessionen mit über 120 Partner-Gemeinden. Bibel TV ist über ASTRA sowie in Deutschland über DVBT2 HD zu empfangen. Bibel TV ist eine gemeinnützige GmbH und hat 16 Gesellschafter, dazu gehören die katholische und die evangelische Kirche in Deutschland mit jeweils 12,75 % der Anteile.

Pressekontakt:

Bibel TV Stiftung gGmbH

Wandalenweg 26

20097 Hamburg

Tel.: +49 (0) 40 / 44 50 66-17

Fax: +49 (0) 40 / 44 50 66-18

E-Mail: presse@bibeltv.de

Original-Content von: Bibel TV, übermittelt durch news aktuell